ClinicalTrials.Veeva

Menu
A

Advanced Research Center, Inc. | Anaheim, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cariprazine
Linaclotide
KarXT
SEP-363856
BHV-7000
Ontamalimab
Ecopipam
Aticaprant
SDX
d-MPH

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

46 of 111 total trials

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

The primary efficacy objective:To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.The secondary effic...

Active, not recruiting
Idiopathic Inflammatory Myositis
Drug: Daxdilimab
Drug: Placebo

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Enrolling
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo (semaglutide)
Drug: Semagludtide

The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age...

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling
Anhedonia
Depressive Disorder, Major
Drug: Aticaprant
Other: Placebo

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Drug: Aticaprant
Other: Placebo

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment d...

Active, not recruiting
Attention Deficit Hyperactivity Disorder
Drug: Guanfacine hydrochloride (TAK-503)
Other: Placebo

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and...

Enrolling
Functional Constipation
Drug: Linaclotide
Drug: Placebo

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and...

Enrolling
Functional Constipation (FC)
Chronic Idiopathic Constipation (CIC)
Drug: Linaclotide
Drug: Placebo for Linaclotide

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: Placebo
Drug: KarXT

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Placebo-Matching Atogepant
Drug: Atogepant

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with mod...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: KarXT

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[...

Enrolling
Tourette Syndrome
Drug: Ecopipam

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling
COVID-19
SARS-CoV-2 Virus
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: BI 425809

Trial sponsors

AbbVie logo
Shire logo
Karuna Therapeutics logo
Otsuka logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo
Biohaven logo
E
Forest Laboratories logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems